» Articles » PMID: 20631066

Recruitment of Myeloid but Not Endothelial Precursor Cells Facilitates Tumor Regrowth After Local Irradiation

Overview
Journal Cancer Res
Specialty Oncology
Date 2010 Jul 16
PMID 20631066
Citations 154
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor neovascularization and growth might be promoted by the recruitment of bone marrow-derived cells (BMDC), which include endothelial precursor cells and "vascular modulatory" myelomonocytic (CD11b+) cells. BMDCs may also drive tumor regrowth after certain chemotherapeutic and vascular disruption treatments. In this study, we evaluated the role of BMDC recruitment in breast and lung carcinoma xenograft models after local irradiation (LI). We depleted the bone marrow by including whole-body irradiation (WBI) of 6 Gy as part of a total tumor dose of 21 Gy, and compared the growth delay with the one achieved after LI of 21 Gy. In both models, the inclusion of WBI induced longer tumor growth delays. Moreover, WBI increased lung tumor control probability by LI. Exogenous delivery of BMDCs from radiation-naïve donors partially abrogated the WBI effect. Myeloid BMDCs, primarily macrophages, rapidly accumulated in tumors after LI. Intratumoral expression of stromal-derived factor 1alpha (SDF-1alpha), a chemokine that promotes tissue retention of BMDCs, was noted 2 days after LI. Conversely, treatment with an inhibitor of SDF-1alpha receptor CXCR4 (AMD3100) with LI significantly delayed tumor regrowth. However, when administered starting from 5 days post-LI, AMD3100 treatment was ineffective. Lastly, with restorative bone marrow transplantation of Tie2-GFP-labeled BMDC population, we observed an increased number of monocytes but not endothelial precursor cells in tumors that recurred following LI. Our results suggest that an increase in intratumoral SDF-1alpha triggered by LI recruits myelomonocytes/macrophages which promotes tumor regrowth.

Citing Articles

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial.

Giordano F, Layer J, Leonardelli S, Friker L, Turiello R, Corvino D Nat Commun. 2024; 15(1):4210.

PMID: 38806504 PMC: 11133480. DOI: 10.1038/s41467-024-48416-9.


Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism.

Yang F, Lee G, Fan Y Angiogenesis. 2024; 27(3):333-349.

PMID: 38580870 PMC: 11303583. DOI: 10.1007/s10456-024-09913-z.


Magnetic Resonance Imaging of Macrophage Response to Radiation Therapy.

Yang H, Howerton B, Brown L, Izumi T, Cheek D, Brandon J Cancers (Basel). 2023; 15(24).

PMID: 38136418 PMC: 10742077. DOI: 10.3390/cancers15245874.


Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy.

Wang Z, Zhang Z, Wu Y, Pi Y, Lou S, Liu T Signal Transduct Target Ther. 2023; 8(1):420.

PMID: 37926722 PMC: 10625992. DOI: 10.1038/s41392-023-01647-6.


Review of possible mechanisms of radiotherapy resistance in cervical cancer.

Zhang H, Wang X, Ma Y, Zhang Q, Liu R, Luo H Front Oncol. 2023; 13:1164985.

PMID: 37692844 PMC: 10484717. DOI: 10.3389/fonc.2023.1164985.


References
1.
Heissig B, Rafii S, Akiyama H, Ohki Y, Sato Y, Rafael T . Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med. 2005; 202(6):739-50. PMC: 2212942. DOI: 10.1084/jem.20050959. View

2.
Loges S, Schmidt T, Carmeliet P . "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF. Clin Cancer Res. 2009; 15(11):3648-53. DOI: 10.1158/1078-0432.CCR-08-2276. View

3.
Du R, Lu K, Petritsch C, Liu P, Ganss R, Passegue E . HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008; 13(3):206-20. PMC: 2643426. DOI: 10.1016/j.ccr.2008.01.034. View

4.
Jin D, Shido K, Kopp H, Petit I, Shmelkov S, Young L . Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med. 2006; 12(5):557-67. PMC: 2754288. DOI: 10.1038/nm1400. View

5.
Kozin S, Winkler F, Garkavtsev I, Hicklin D, Jain R, Boucher Y . Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors. Cancer Res. 2007; 67(11):5076-82. DOI: 10.1158/0008-5472.CAN-06-3664. View